Skip to main content

Resources

Insights for Drug Development Leaders

Strategy, execution, and clarity for teams navigating early drug development. Actionable frameworks from 20+ years of building roadmaps that reach the clinic.

Emerging biopharma now accounts for 56% of all new drug launches, up from 35% in 2013. These teams need sharper strategy, not bigger budgets.

These insights are adapted from Dr. Rodriguez's LinkedIn posts, where she publishes weekly on drug development strategy.

Browse by Category

Strategy

5 articles

Target Product Profile

2 articles

Execution & Team

2 articles

Regulatory Strategy

1 article

Strategy

Strategy in Early Drug Development: Why Clarity is Your Most Valuable Asset

Drug development strategy is not a 30-slide deck. It is a single page of explicit choices about what you will and will not do to reach your goal. Most early-stage teams confuse plans with strategy. They are not the same thing.

Read
TPP

The Power of the Target Product Profile

A Target Product Profile is a plain-language blueprint of the drug you intend to bring to patients. It forces you to make explicit choices about your product characteristics, your patient population, and your evidence gaps. Without it, your team is building without a foundation.

Read
Strategy

From Drug Concept to Clinic: Cultivating a Translational Mindset

Investors do not write checks for cool scientific ideas. They fund strategies with the potential to transform science into viable drug products. A translational mindset bridges the gap between your research and the capital needed to advance it.

Read
Strategy

Building Drug Development Strategies One Puzzle Piece at a Time

Strategy is not goals and aspirations. It is not plans and experimental workflows. It is not your mission and vision statement. Strategy is about making explicit choices. This is the first in a five-part series on building a drug development strategy on a page.

Read
Execution

Prioritize Everything and Focus Disappears

If everything is a priority, nothing is a priority. Early-stage drug development teams face this trap constantly. The solution is not working harder. The solution is making clearer choices about what you will and will not do.

Read
Strategy

Breaking the Status Quo: Why Optimization Is Not a Strategy

The status quo is not where you will find drug innovation. It is where concepts lead to incremental changes in value. True strategy requires creating new market spaces, not optimizing your position in crowded ones.

Read
Regulatory

Pre-IND Meetings: What FDA Wants to See Before Your First Submission

A Pre-IND meeting is your opportunity to align with FDA before committing to a clinical development program. But preparation is critical. Come unprepared and you waste the meeting and delay your program. Here are the questions FDA expects you to answer.

Read
Strategy

The Five Choices That Define Every Drug Development Strategy

Every successful drug development strategy rests on five integrated choices: indication selection, patient population definition, competitive positioning, evidence strategy, and regulatory pathway. Skip or misalign even one, and the entire strategy collapses.

Read
TPP

Endpoints Matter: Choosing the Right Clinical Measures for Your Drug

Endpoints are not a regulatory checkbox. They are the language by which FDA understands whether your drug is safe and effective. Poor endpoint choices delay programs by years. Strong endpoint choices accelerate them.

Read
Execution

Team Alignment on Strategy: Why Your CMC, Clinical, and Regulatory Teams Must Speak One Language

A strategy that lives only in one department is not a strategy—it is a silo. This article explores how to build alignment across chemistry, clinical development, and regulatory affairs so every decision reinforces the others.

Read

Guides & Templates

Practical tools built from real program execution. Available to Strategy Sprint participants.

TPP Template

A Target Product Profile template with guidance notes for each section. Define your product characteristics, patient population, and evidence requirements.

Available in Strategy Sprint

Development Checklist

Pre-IND development checklist covering CMC, nonclinical, and clinical readiness. Built from real program execution.

Available in Strategy Sprint

Strategy on a Page Template

One-page drug development strategy template. Forces clarity on choices, evidence gaps, and the roadmap to your next inflection point.

Available in Strategy Sprint

Follow the Journey

New insights on drug development strategy published weekly on LinkedIn. Subscribe below for monthly digests delivered to your inbox.

Follow Dr. Rodriguez on LinkedIn

No spam. Unsubscribe anytime. One email per month.